Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
NerdWallet Inc Q1 2026 Earnings Call - Record Profitability Masks Auto Insurance Headwinds and Aggressive Vertical Integration Bets
NerdWallet delivered a quarter of stark contrasts. Revenue grew 6% to $222 million, but the profit story stole the show. Non-GAAP operating income hit a record $34 million, driven by a deliberate sque...
- Total revenue reached $222 million, up 6% year-over-year, with consumer revenue driving the growth at $198 million, up 10% year-over-year.
- Non-GAAP operating income hit a record $34 million, significantly beating the guidance range of $28 million to $32 million and up from $9 million in the prior-year quarter.
- Adjusted EBITDA also set a new Q1 record at $45 million, supported by strong operating leverage and a sharp reduction in other marketing spend.
- +7 more takeaways
Ibotta Q1 2026 Earnings Call - Revenue Declines Slow, LiveLift Momentum Builds, and Two Exclusive Publisher Wins Signal a Shift
Ibotta delivered another quarter of execution beats, with revenue and Adjusted EBITDA landing above the top end of guidance, even as total revenue declined 2% year-over-year. The core story is a gradu...
- Q1 2026 revenue was $82.5 million, a 2% year-over-year decline, but both revenue and Adjusted EBITDA exceeded the top end of guidance, signaling strong execution.
- Redemption revenue declined only 1% year-over-year, a significant improvement from the 15% drop in Q3 2025 and 5% drop in Q4 2025, pointing to a clear bottom in the decline.
- Total redeemers grew 15% year-over-year to 19.7 million, with third-party publisher redemption revenue surging 12% year-over-year to $54 million, demonstrating the success of the IPN expansion.
- +10 more takeaways
Mineralys Therapeutics Q1 2026 Earnings Call - FDA Accepts NDA for Lorundrostat, PDUFA Set for December 2026
Mineralys Therapeutics received FDA acceptance of its New Drug Application for lorundrostat, a novel aldosterone synthase inhibitor targeting uncontrolled or resistant hypertension. The FDA has set a ...
- FDA accepted the NDA for lorundrostat for hypertension in combination with other antihypertensive drugs, with a PDUFA target date of December 22, 2026.
- Lorundrostat's NDA is supported by five pivotal trials: Launch-HTN, Advance-HTN, Transform-HTN, Target-HTN, and Explore-CKD, demonstrating clinically meaningful blood pressure reductions.
- Mineralys ended Q1 2026 with $646.1 million in cash equivalents and investments, sufficient to fund operations into 2028.
- +7 more takeaways
Magnite Q1 2026 Earnings Call - CTV Contribution Exceeds DV+ as AI and Commerce Media Drive Margin Expansion
Magnite delivered a decisive Q1 2026 performance, with CTV contribution ex-TAC surging 30% to capture 51% of total contribution for the first time. The shift away from traditional DV+ is no longer a h...
- CTV contribution ex-TAC grew 30% year-over-year to $82 million, surpassing DV+ to represent 51% of total contribution for the first time.
- Total revenue reached $164 million, up 6% year-over-year, with Adjusted EBITDA of $43 million and a 27% margin, beating consensus by $5 million.
- DV+ contribution ex-TAC declined 5% to $79 million, but management noted stabilization trends in mobile in-app, audio, and commerce media.
- +9 more takeaways
ADMA Biologics Q1 2026 Earnings Call - ASCENIV Demand Remains Robust Amid Standard IG Market Dislocation
ADMA Biologics reported flat top-line revenue in Q1 2026, but adjusted net income surged 22% year-over-year, driven by margin expansion and disciplined cost management. The core narrative centers on a...
- Total revenue came in flat year-over-year at $114.5 million, masking a significant product mix shift between ASCENIV and BIVIGAM.
- ASCENIV revenue grew 28% year-over-year to $97.5 million, supported by record new patient starts, prescriber adoption, and patient adherence.
- BIVIGAM revenue collapsed 54% year-over-year to $15.4 million, disproportionately impacted by aggressive discounting and inventory buildup from new standard IG entrants.
- +7 more takeaways
The ONE Group Q1 2026 Earnings Call - Margin Expansion Driven by Supply Chain Discipline and Portfolio Optimization
The ONE Group delivered a quarter defined by operational discipline rather than macroeconomic tailwinds. Total GAAP revenues rose 0.8% to $213 million, while consolidated comparable sales remained fla...
- Total GAAP revenues increased 0.8% year-over-year to $213 million, driven by a fiscal calendar shift moving New Year's Eve into Q1 and new openings, partially offset by grill closures.
- Consolidated comparable sales were flat at negative 0.3%, with U.S. STK up 1.4%, Benihana flat, and the growth concept down 4.9% but showing positive transaction momentum.
- Restaurant operating profit rose 11% to $40 million, with margins expanding 100 basis points to 19%, fueled by a 140 basis point reduction in food and beverage costs.
- +7 more takeaways
BillionToOne Q1 2026 Earnings Call - Profitable Growth Accelerates with Unity Confirm Launch and Anthem Contract
BillionToOne delivered a quarter of compounding growth and rare profitability for a high-growth molecular diagnostics company. Revenue surged 84% year-over-year to $108.4 million, driven by a 44% incr...
- Revenue grew 84% year-over-year to $108.4 million, with test volumes up 44% and ASPs rising 28% to $571 per test.
- GAAP operating margin reached 16% and adjusted EBITDA margin hit 24%, marking the third consecutive quarter of Rule of 100+ performance paired with profitability.
- Gross margins expanded 9 percentage points year-over-year to 73%, driven by prenatal ASP growth and COGS reductions in oncology.
- +7 more takeaways
"Chegg, Inc." Q1 2026 Earnings Call - AI-Driven Skilling Growth and Balance Sheet Strength
Chegg delivered a strong Q1 2026, surpassing revenue, profitability, and free cash flow expectations while aggressively reducing debt. The company's strategic pivot to an AI-first model is yielding ta...
- Chegg exceeded Q1 2026 expectations across revenue, profitability, and free cash flow, signaling a successful turnaround under renewed leadership.
- Chegg Skilling revenue reached $17.6 million, up 9% year-over-year, with management targeting double-digit full-year growth driven by new enterprise and channel partnerships.
- The company has re-architected its product and cost base around AI, enabling faster content creation, real-time learning interventions, and a 55% year-over-year reduction in non-GAAP operating expenses.
- +7 more takeaways
Savers Value Village Q1 2026 Earnings Call - Thrift Adoption Accelerates in U.S. While Canada Optimizes for Margin
Savers Value Village delivered a strong start to 2026 with U.S. comp sales jumping 6.4%, fueled by broad-based demand across income cohorts and a powerful secular shift toward secondhand shopping. The...
- U.S. comp sales grew 6.4%, driven by gains in both average basket size and transaction counts, signaling broad-based consumer adoption across income demographics.
- Canadian comp sales declined 0.6%, primarily due to a 70 basis point headwind from an early Easter, but macro conditions remain sluggish in key markets like Southern Ontario.
- Canadian segment profit surged 24% year-over-year, expanding margins by 310 basis points through tight production management and offsite efficiency initiatives.
- +9 more takeaways
LifeMD Q1 2026 Earnings Call - Record Subscriber Growth and Strategic Pivot to Branded GLP-1s and Insurance-Backed Care
LifeMD reported a strong first quarter of 2026, delivering $50.2 million in revenue and adding 42,000 net telehealth subscribers, marking the largest quarterly net addition in the company's history. T...
- LifeMD delivered Q1 2026 revenue of $50.2 million, exceeding guidance and marking a strong start to the year despite flat year-over-year growth due to a product mix shift.
- The company added 42,000 net telehealth subscribers in Q1, the largest quarterly net addition in its history, ending the quarter with over 365,000 active subscribers.
- Weight management sign-ups surged approximately 120% sequentially, driven by the launch of oral GLP-1 therapies and improved customer acquisition economics.
- +7 more takeaways